Antiproliferative activity against human KMS-11 cells assessed as reduction in cell viability incubated for 48 hrs by propidium iodide staining-based flow cytometric analysis
Displacement of [3H]estradiol from human full length recombinant ERalpha expressed in baculovirus-infected Sf9 cells at 5 uM incubated for 120 mins by radiometric scintillation counting analysis
Displacement of [3H]estradiol from human full length recombinant ERalpha expressed in baculovirus-infected Sf9 cells at 50 uM incubated for 120 mins by radiometric scintillation counting analysis
Displacement of [3H]estradiol from human full length recombinant ERbeta expressed in baculovirus-infected Sf9 cells at 5 uM incubated for 120 mins by radiometric scintillation counting analysis
Displacement of [3H]estradiol from human full length recombinant ERbeta expressed in baculovirus-infected Sf9 cells at 50 uM incubated for 120 mins by radiometric scintillation counting analysis
Antitumor activity against human KMS-11 cells xenografted in NOD-SCID mouse assessed as tumor growth inhibition at 7.5 mg/kg, ip administered every other day measured at day 17 post-tumor implantation by caliper analysis
Antiproliferative activity against human OPM-2 cells assessed as reduction in cell viability incubated for 48 hrs by propidium iodide staining-based flow cytometric analysis
Antiproliferative activity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 48 hrs by propidium iodide staining-based flow cytometric analysis
Antiproliferative activity against human U-266 cells assessed as reduction in cell viability incubated for 48 hrs by propidium iodide staining-based flow cytometric analysis
Drug metabolism in NOD-SCID mouse plasma assessed as (1R)-4,4,4-trifluoro-1-((3S,10R,13S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-3-(trifluoromethyl)butane-1,3-diol formation at 7.5 mg/kg, ip measured after 90 mins by HPLC-MS/MS analysis